By LabPulse.com staff writers

August 13, 2019 -- A liquid biopsy blood test for breast cancer shows promise for monitoring disease progression and helping patients avoid unnecessary surgeries, according to a research article published online August 7 in Science Translational Medicine.

The targeted digital sequencing (TARDIS) test is up to 100 times more sensitive than other blood-based cancer monitoring tests, concluded the group led by Bradon McDonald from the Translational Genomics Research Institute in Phoenix.

Also, it is precise enough to show whether early-stage breast cancer patients have responded to drug therapy before surgery. The test is able tell early on whether treatment is working, potentially as soon as after once cycle, according to the researchers.

TARDIS works by identifying and quantifying small amounts of circulating tumor DNA (ctDNA) -- as few as two parts per 100,000 in a patient's blood.

The sensitivity of the TARDIS test make it a more precise tool than imaging, and it is less invasive than traditional biopsies, which only provide results for one area at a time. Because liquid biopsies only require a blood draw, they can be performed safely as needed to check a person's disease status.

The study authors hope the TARDIS test could eventually be routinely used to track patients' cancer treatment progress and discover when they are disease-free.

Liquid biopsy test detects biomarker for immunotherapy
Precision oncology company Guardant Health is touting a new study confirming that its Guardant360 liquid biopsy test can accurately detect microsatellite...
In vivo liquid biopsy method demonstrated in melanoma
Results of in vivo liquid biopsy using an investigational laser- and imaging-based platform suggest higher sensitivity for detecting circulating tumor...
Machine learning helps liquid biopsy detect cancer based on DNA
A new liquid biopsy blood test under development at Johns Hopkins University could detect up to seven types of cancer by using machine learning to help...
Liquid biopsies show the way in melanoma and rectal cancer
The potential role for circulating tumor DNA in guiding treatment and monitoring response received more support from a pair of separate studies on rectal...
Liquid biopsy results help TARGET cancer treatments in U.K. study
Circulating tumor DNA tests are practical for genomic profiling of tumors and guiding cancer patients to early-stage clinical trials of targeted therapies...

Copyright © 2019 LabPulse.com

Last Updated np 8/12/2019 5:09:46 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email